Short-course versus prolonged-course antibiotic therapy for hospital-acquired pneumonia in critically ill adults

Cochrane Database of Systematic Reviews

Volumn 2015, Issue 8, 2015, Pages

  Pugh, Richard ^a   Grant, Chris ^b   Cooke, Richard P D ^c   Dempsey, Ged ^b  

^a GLAN CLWYD HOSPITAL   (United Kingdom)

^b UNIVERSITY HOSPITAL AINTREE   (United Kingdom)

^c ALDER HEY CHILDREN'S NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT;

ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTIFICIAL VENTILATION; BACTERIAL SUPERINFECTION; CRITICALLY ILL PATIENT; GRAM NEGATIVE BACTERIUM; HOSPITAL ACQUIRED PNEUMONIA; HOSPITALIZATION; HUMAN; INFECTION RISK; LONG TERM CARE; META ANALYSIS; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; SHORT COURSE THERAPY; SYSTEMATIC REVIEW; TREATMENT DURATION; CRITICAL ILLNESS; CROSS INFECTION; DRUG ADMINISTRATION; INTENSIVE CARE UNIT; MICROBIOLOGY; PNEUMONIA; PNEUMONIA, VENTILATOR-ASSOCIATED; RANDOMIZED CONTROLLED TRIAL (TOPIC); TIME FACTOR;

ADULT; ANTI-BACTERIAL AGENTS; CRITICAL ILLNESS; CROSS INFECTION; DRUG ADMINISTRATION SCHEDULE; HUMANS; INTENSIVE CARE UNITS; PNEUMONIA; PNEUMONIA, VENTILATOR-ASSOCIATED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TIME FACTORS;

EID: 84991203350     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD007577.pub3     Document Type: Review

References (98)

1. Capellier G, Mockly H, Charpentier C, Annane D, Blasco G, Desmettre T, et al. Early-onset ventilator-associated pneumonia in adults randomized clinical trial: comparison of 8 versus 15 days of antibiotic treatment. PloS One 2012;7(8):e41290.
2. Chastre J, Wolff M, Fagon JY, Chevret S, Thomas F, Wermert D, et al. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA 2003;290(19):2588-98.
3. Fekih Hassen M, Ayed S, Ben Sik Ali H, Gharbi R, Marghli S, Elatrous S. Duration of antibiotic therapy for ventilator-associated pneumonia: comparison of 7 and 10 days. A pilot study. Annales Françaises d'Anesthésie et de Réanimation 2009;28(1):16-23.
4. Kollef M, Chastre J, Restrepo M, Michiels B, Kaniga K, Cirillo I, et al. A randomized trial of 7-day doripenem versus 10-day imipenem-cilastatin for ventilator-associated pneumonia. Critical Care 2012;16:R218.
5. Medina JC, Perez Protto SE, Paciel D, Pontet J, Saldun P, Berro M. Antibiotic treatment for the ventilator-associated pneumonia: 8 vs. 12 days randomized trial preliminary data. Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL. 2007.
6. Singh N, Rogers P, Atwood CW, Wagener MM, Yu VL. Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. A proposed solution for indiscriminate antibiotic prescription. American Journal of Respiratory and Critical Care Medicine 2000;162:505-11.
7. Bouadma L, Luyt CE, Tubach F, Cracco C, Alvarez A, Schwebel C, et al. Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet 2010;375(9713):463-74.
8. Cai S, Zhang J, Qian G. Impact of quantitative and qualitative pathogen culture on the outcome of ventilator-associated pneumonia. Zhonghua Jie He He Hu Xi Za Zhi 2001;24(8):494-7.
9. Canadian Critical Care Trials Group. A randomized trial of diagnostic techniques for ventilator-associated pneumonia. New England Journal of Medicine 2006;355(25):2619-30.
10. Chastre J, Wolff M, Fagon JY, Chevret S. Comparison of two durations of antibiotic therapy to treat ventilator-associated pneumonia (VAP). American Thoracic Society Meeting, Seattle, Washington. 2003:A015.
11. Fagon JY, Chastre J, Wolff M, Gervais C, Parer-Aubas S, Stéphan F, et al. Invasive and noninvasive strategies for management of suspected ventilator-associated pneumonia. A randomized trial. Annals of Internal Medicine 2000;132(8):621-30.
12. Hochreiter M, Köhler T, Schweiger AM, Keck FS, Bein B, von Spiegel T, et al. Procalcitonin to guide duration of antibiotic therapy in intensive care patients: a randomized prospective controlled trial. Critical Care 2009;13(3):R83.
13. Ibrahim EH, Ward S, Sherman G, Schaiff R, Fraser VJ, Kollef MH. Experience with a clinical guideline for the treatment of ventilator-associated pneumonia. Critical Care Medicine 2001;29(6):1109-15.
14. Kim JW, Chung J, Jang HJ, Hong SB, Lim CM, Koh Y. De-escalation of antibiotics in critically ill patients with hospital-acquired pneumonia. Respirology. 2009; Vol. 14:A129.
15. Kim JW, Chung J, Choi SH, Jang HJ, Hong SB, Lim CM, et al. Early use of imipenem/cilastatin and vancomycin followed by de-escalation versus conventional antimicrobials without de-escalation for patients with hospital-acquired pneumonia in a medical ICU: a randomized clinical trial. Critical Care 2012;16(1):R28.
16. Kollef MH, Kollef KE. Antibiotic utilization and outcomes for patients with clinically suspected ventilator-associated pneumonia and negative quantitative BAL culture results. Chest 2005;128:2706-13.
17. Labelle AJ, Schoenberg N, Skrupky L, Kollef M. Five versus seven day antibiotic course for the treatment of pneumonia in the intensive care unit. American Journal of Respiratory and Critical Care Medicine. 2012; Vol. 185:A6078.
18. Maldonado-Ortiz EA, Niederman MS, Nacul F, Rodríguez A, Ceballos S, Osorio J. How long is enough to treat ventilator associated pneumonia? A randomized pilot study: the Latinoamerican experience. Chest 2004;126(Suppl 4):717.
19. Micek ST, Ward S, Fraser VJ, Kollef MH. A randomized controlled trial of an antibiotic discontinuation policy for clinically suspected ventilator-associated pneumonia. Chest 2004;125(5):1791-9.
20. Nobre V, Harbarth S, Graf JD, Rohner P, Pugin J. Use of procalcitonin to shorten antibiotic treatment duration in septic patients: a randomized trial. American Journal of Respiratory and Critical Care Medicine 2008;177(5):498-505.
21. Peery C, Chendrasekhar A, Moorman DW, Timberlake GA. Ventilator-associated pneumonia therapy: protected specimen brushing versus tracheal aspirate data. Journal of Applied Research 2001;1(2):1.
22. Pontet J, Paciel D, Olivera W, Bentancourt S, Cancela M, Gervas J. Procalcitonin (PCT) guided antibiotic treatment in ventilator associated pneumonia (VAP). Multi-centre, clinical prospective, randomized-controlled study. American Thoracic Society International Conference, San Francisco, California, USA. 2007:A76.
23. Rello J, Vidaur L, Sandiumenge A, Rodríguez A, Gualis B, Boque C, et al. De-escalation therapy in ventilator-associated pneumonia. Critical Care Medicine 2004;32(11):2183-90.
24. Sanchez-Nieto JM, Torres A, Garcia-Cordoba F, El-Ebiary M, Carrillo A, Ruiz J, et al. Impact of invasive and noninvasive quantitative culture sampling on outcome of ventilator-associated pneumonia: a pilot study. American Journal of Respiratory and Critical Care Medicine 1998;157(2):371-6.
25. Schroeder S, Hochreiter M, Koehler T, Schweiger AM, Bein B, Keck FS, et al. Procalcitonin (PCT)-guided algorithm reduces length of antibiotic treatment in surgical intensive care patients with severe sepsis: results of a prospective randomized study. Langenbeck's Archives of Surgery 2009;394:221-6.
26. Singh N. Short-course empiric antibiotic therapy for suspected nosocomial pneumonia: a proposed solution for indiscriminate antibiotic prescription for pulmonary infiltrates in the ICU. Annual Meeting of the Infectious Disease Society of America, Denver, Colorado. 1998.
27. Sole VJ, Fernandez JA, Benitez AB, Cardenosa Cendrero JA, Rodriguez de CF. Impact of quantitative invasive diagnostic techniques in the management and outcome of mechanically ventilated patients with suspected pneumonia. Critical Care Medicine 2000;28(8):2737-41.
28. Stolz D, Smyrnios N, Eggimann P, Pargger H, Thakkar N, Siegemund M, et al. Procalcitonin for reduced antibiotic exposure in ventilator-associated pneumonia: a randomised study. European Respiratory Journal 2009;34(6):1364-75.
29. Stolz D, Smyrnios N, Eggimann P, Pargger H, Thakkar N, Siegemund M, et al. Procalcitonin for antibiotic de-escalation in ventilator associated pneumonia - a randomized study. European Respiratory Society Annual Congress, Vienna. 2009:2798.
30. Svoboda P, Kantorová I, Scheer P, Radvanova J, Radvan M. Can procalcitonin help us in timing of re-intervention in septic patients after multiple trauma or major surgery?. Hepatogastroenterology 2007;54:359-63.
31. Wolff M, Chastre J, Fagon JY, Chevret S. Comparison of two durations of antibiotic therapy for ventilator-associated pneumonia (VAP) caused by non-fermenting gram negative bacilli (NF-GNB). American Thoracic Society Meeting Seattle, Washington. 2003:A860.
32. Effectiveness of short-course versus standard antibiotic therapy in ICU patients. http://clinicaltrials.gov/ct2/show/study/NCT00410527 2006 (accessed 5 June, 2015).
33. Five versus seven day antibiotic course for the treatment of pneumonia in the intensive care unit. https://clinicaltrials.gov/show/NCT01554657 2012 (accessed 5 June, 2015).
34. Duration of antibiotic treatment for early VAP. http://clinicaltrials.gov/show/NCT01994980 2013 (accessed 5 June, 2015).
35. Agrafiotis M, Siempos II, Falagas ME. Frequency, prevention, outcome and treatment of ventilator-associated tracheobronchitis: systematic review and meta-analysis. Respiratory Medicine 2010;104:325-36.
36. American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. American Journal of Respiratory and Critical Care Medicine 2005;171(4):388-416.
37. Bekaert M, Timsit JF, Vansteelandt S, Depuydt P, Vésin A, Garrouste-Orgeas M, et al. Attributable mortality of ventilator-associated pneumonia: a reappraisal using causal analysis. American Journal of Respiratory and Critical Care Medicine 2011;184(10):133-9.
38. Bignardi GE. Risk factors for Clostridium difficile infection. Journal of Hospital Infection 1998;40(1):1-15.
39. Blot S, Koulenti D, Dimopoulos G, Martin C, Komnos A, Krueger WA, et al. Prevalence, risk factors, and mortality for ventilator-associated pneumonia in middle-aged, old, and very old critically ill patients. Critical Care Medicine 2014;42:601-9.
40. Boyer AF, Schoenberg N, Babcock H, McMullen KM, Micek ST, Kollef MH. A prospective evaluation of ventilator-associated conditions and infection-related ventilator-associated conditions. Chest 2015;147:68-81.
41. Masterton RG, Galloway A, French G, Street M, Armstrong J, Brown E, et al. Guidelines for the management of hospital-acquired pneumonia in the UK: report of the working party on hospital-acquired pneumonia of the British Society for Antimicrobial Chemotherapy. Journal of Antimicrobial Chemotherapy 2008;62(1):5-34.
42. Burgmann H, Hiesmayer J, Savey A, Bauer P, Metnitz B, Metnitz P. Impact of nosocomial infections on clinical outcome and resource consumption in critically ill patients. Intensive Care Medicine 2010;36:1597-601.
43. Chant C, Leung A, Friedrich JO. Optimal dosing of antibiotics in critically ill patients by using continuous/extended infusions: a systematic review and meta-analysis. Critical Care 2012;17:R279.
44. Chastre J, Fagon JY. Ventilator-associated pneumonia. American Journal of Respiratory and Critical Care Medicine 2002;165:867-903.
45. Combes A, Luyt CE, Fagon JY, Wolff M, Trouillet JL, Chastre J. Early predictors for infection recurrence and death in patients with ventilator-associated pneumonia. Critical Care Medicine 2007;35(1):146-54.
46. Morris AC, Kefala K, Simpson AJ, Wilkinson TS, Everingham K, Kerslake D, et al. Evaluation of the effect of diagnostic methodology on the reported incidence of ventilator-associated pneumonia. Thorax 2011;64:516-22.
47. Dallas J, Skrupky L, Abebe N, Boyle W, Kollef M. Ventilator-associated tracheobronchitis in a mixed surgical and medical ICU population. Chest 2011;139:513-8.
48. Deeks JJ, Higgins JPT, Altman DG (editors). Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
49. Dennesen PJ, van der Ven AJ, Kessels AG, Ramsay G, Bonten MJ. Resolution of infectious parameters after antimicrobial therapy in patients with ventilator-associated pneumonia. American Journal of Respiratory and Critical Care Medicine 2001;163(6):1371-5.
50. Dimopoulos G, Poulakou G, Pneumatikos IA, Armaganidis A, Kollef MH, Matthaiou DK. Short- versus long-duration antibiotic regimens for ventilator-associated pneumonia: a systematic review and meta-analysis. Chest 2013;144:1759-67.
51. Dubberke E, Carling P, Carrico R, Donskey C, Loo V, McDonald L, et al. Strategies to prevent Clostridium difficile infections in acute care hospitals: 2014 Update. Infection Control and Hospital Epidemiology 2014;35:628-45.
52. Dugan HA, MacLaren R, Jung R. Duration of antimicrobial therapy for nosocomial pneumonia: possible strategies for minimizing antimicrobial use in intensive care units. Journal of Clinical Pharmacy and Therapeutics 2003;28(2):123-9.
53. El Solh AA, Choi G, Schultz MJ, Pineda LA, Mankowski C. Clinical and hemostatic responses to treatment in ventilator-associated pneumonia: role of bacterial pathogens. Critical Care Medicine 2007;35(2):490-6.
54. Esperatti M, Ferrer M, Theessen A, Liapikou A, Valencia M, Saucedo L, et al. Nosocomial pneumonia in the intensive care unit acquired by mechanically ventilated versus nonventilated patients. American Journal of Respiratory and Critical Care Medicine 2010;182:1533-9.
55. US Food, Drug Administration. FDA approves label changes for antibacterial Doribax (doripenem) describing increased risk of death for ventilator patients with pneumonia. FDA Drug Safety Communication 2014:http://www.fda.gov/Drugs/DrugSafety/ucm387971.htm (accessed 4 May 2015).
56. Gastmeier P, Sohr D, Geffers C, Rüden H, Vonberg R, Welte T. Early- and late-onset pneumonia: is this still a useful classification?. Antimicrobial Agents and Chemotherapy 2009;53:2714-8.
57. Grammatikos AP, Siempos II, Michalopoulos A, Falagas ME. Optimal duration of the antimicrobial treatment of ventilator-acquired pneumonia. Expert Review of Anti-infective Therapy 2008;6(6):861-6.
58. Hayashi Y, Morisawa K, Klompas M, Jones M, Bandeshe H, Boots R, et al. Toward improved surveillance: the impact of ventilator-associated complications on length of stay and antibiotic use in patients in intensive care units. Clinical Infectious Disease 2013;56:471-7.
59. Hospital in Europe Link for Infection Control through Surveillance (HELICS). Surveillance of Nosocomial infections in intensive care units, Protocol Version 6.1. http://ecdc.europa.eu/en/activities/surveillance/HAI/Documents/0409_IPSE_ICU_protocol.pdf 2004 (accessed 9 January 2015).
60. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Statistics in Medicine 2002;21:1539-58.
61. Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. American Journal of Infection Control 2008;36:309-32.
62. Jensen JU, Hein L, Lundgren B, Bestle MH, Mohr TT, Andersen MH, et al. Procalcitonin-guided interventions against infections to increase early appropriate antibiotics and improve survival in the intensive care unit: a randomized trial. Critical Care Medicine 2011;39:2048-58.
63. Kipnis E, Nseir S. Ventilator-associated events (VAEs): VAE Victis? (Woe to the conquered?)*. Critical Care Medicine 2014;42(8):1949-50.
64. Klein Klouwenberg P, van Mourik M, Ong D, Horn J, Schultz M, Cremer O, et al. Electronic implementation of a novel surveillance paradigm for ventilator-associated events. Feasibility and validation. American Journal of Respiratory and Critical Care Medicine 2014;189:947-55.
65. Kohlenberg A, Schwab F, Behnke M, Geffers C, Gastmeier P. Pneumonia associated with invasive and noninvasive ventilation: an analysis of the German nosocomial infection surveillance system database. Intensive Care Medicine 2010;36(6):971-8.
66. Kollef MH, Silver P, Murphy DM, Trovillion E. The effect of late-onset ventilator-associated pneumonia in determining patient mortality. Chest 1995;108(6):1655-62.
67. Kollef MH, Micek ST. Antimicrobial stewardship programs: mandatory for all ICUs. Critical Care 2012;16(6):179.
68. Kopterides P, Siempos II, Tsangaris I, Tsantes A, Armaganidis A. Procalcitonin-guided algorithms of antibiotic therapy in the intensive care unit: a systematic review and meta-analysis of randomized controlled trials. Critical Care Medicine 2010;38(11):2229-41.
69. Koulenti D, Lisboa T, Brun-Buisson C, Krueger W, Macor A, Sole-Violan J, et al. Spectrum of practice in the diagnosis of nosocomial pneumonia in patients requiring mechanical ventilation in European intensive care units. Critical Care Medicine 2009;37:2360-8.
70. Lefebvre C, Manheimer E, Glanville J. Chapter 6. Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
71. Luna CM, Blanzaco D, Niederman MS, Matarucco W, Baredes NC, Desmery P, et al. Resolution of ventilator-associated pneumonia: prospective evaluation of the clinical pulmonary infection score as an early clinical predictor of outcome. Critical Care Medicine 2003;31(3):676-82.
72. Magill S, Klompas M, Balk R, Burns SM, Deutschman C, Diekema D, et al. Developing a new, national approach to surveillance for ventilator-associated events. Critical Care Medicine 2013;41:2467-75.
73. Martin-Loeches I, Torres A, Rinaudo M, Terraneo S, de Rosa F, Ramirez P, et al. Resistance patterns and outcomes in intensive care unit (ICU)-acquired pneumonia. Validation of European Centre for Disease Prevention and Control (ECDC) and the Centers for Disease Control and Prevention (CDC) classification of multidrug resistant organisms. Journal of Infection 2015;70:213-22.
74. Melsen WG, Rovers MM, Koeman M, Bonten MJ. Estimating the attributable mortality of ventilator-associated pneumonia from randomized prevention studies. Critical Care Medicine 2011;39(12):2736-42.
75. Melsen WG, Rovers MM, Groenwold RH, Bergmans DC, Camus C, Bauer TT, et al. Attributable mortality of ventilator-associated pneumonia: a meta-analysis of individual patient data from randomised prevention studies. Lancet Infectious Diseases 2013;13(8):665-71.
76. Mueller EW, Croce MA, Boucher BA, Hanes SD, Wood GC, Swanson JM, et al. Repeat bronchoalveolar lavage to guide antibiotic duration for ventilator-associated pneumonia. Journal of Trauma 2007;63(6):1329-37.
77. Muscedere J, Sinuff T, Heyland D, Dodek P, Keenan S, Wood G, et al. The clinical impact and preventability of ventilator-associated conditions in critically ill patients who are mechanically ventilated. Chest 2013;144:1453-60.
78. Niederman MS, Chastre J, Corkery K, Fink JB, Luyt CE, García MS. BAY41-6551 achieves bactericidal tracheal aspirate amikacin concentrations in mechanically ventilated patients with Gram-negative pneumonia. Intensive Care Medicine 2012;38:263-71.
79. Rello J, Ollendorf DA, Oster G, Vera-Llonch M, Bellm L, Redman R, et al. Epidemiology and outcomes of ventilator-associated pneumonia in a large US database. Chest 2002;122:2115-21.
80. Restrepo M, Peterson J, Fernandez J, Qin Z, Fisher A, Nicholson S. Comparison of the bacterial etiology of early-onset and late-onset ventilator-associated pneumonia in subjects enrolled in 2 large clinical studies. Respiratory Care 2013;58:1220-5.
81. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
82. Richards MJ, Edwards JR, Culver DH, Gaynes RP. Nosocomial infections in combined medical-surgical intensive care units in the United States. Infection Control and Hospital Epidemiology 2000;21(8):510-5.
83. Rotstein C, Evans G, Born A, Grossman R, Light RB, Magder S, et al. Clinical practice guidelines for hospital-acquired pneumonia and ventilator-associated pneumonia in adults. Canadian Journal of Infectious Diseases and Medical Microbiology 2008;19(1):19-53.
84. Safdar N, Dezfulian C, Collard HR, Saint S. Clinical and economic consequences of ventilator-associated pneumonia: a systematic review. Critical Care Medicine 2005;33:2184-93.
85. Schuetz P, Briel M, Christ-Crain M, Stolz D, Bouadma L, Wolff M, et al. Procalcitonin to guide initiation and duration of antibiotic treatment in acute respiratory infections: an individual patient data meta-analysis. Clinical Infectious Diseases 2012;55:651-62.
86. Schuetz P, Müller B, Christ-Crain M, Stolz D, Tamm M, Bouadma L, et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Cochrane Database of Systematic Reviews 2012, Issue 9. [DOI: 10.1002/14651858.CD007498.pub2]
87. Sharpe JP, Magnotti LJ, Weinberg JA, Swanson JM, Schroeppel TJ, Clement LP, et al. Adherence to an established diagnostic threshold for ventilator-associated pneumonia contributes to low false-negative rates in trauma patients. Journal of Trauma and Acute Care Surgery 2015;78(3):468-73.
88. Sterne JAC, Egger M, Moher D (editors). Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
89. Stoeppel CM, Eriksson EA, Hawkins K, Eastman A, Wolf S, Minei J, et al. Applicability of the National Healthcare Safety Network's surveillance definition of ventilator-associated events in the surgical intensive care unit: a 1-year review. Journal of Trauma and Acute Care Surgery 2014;77:934-7.
90. Szakmany T, Harrison W, Roberts H, Scholey G, Pugh R. Surveillance for ventilator-associated pneumonia (VAP) in Wales: is HELICS the best way?. Critical Care Medicine 2013;41(Suppl 12):46.
91. Vincent JL, Bihari DJ, Suter PM, Bruining HA, White J, Nicolas-Chanoin MH, et al. The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee. JAMA 1995;274(8):639-44.
92. Vincent JL, Rello J, Marshall J, Silva E, Anzueto A, Martin CD, et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA 2009;302(21):2323-9.
93. Visscher S, Schurink CA, Melsen WG, Lucas PJ, Bonten MJ. Effects of systemic antibiotic therapy on bacterial persistence in the respiratory tract of mechanically ventilated patients. Intensive Care Medicine 2008;34(4):692-9.
94. Warren DK, Shukla SJ, Olsen MA, Kollef MH, Hollenbeak CS, et al. Outcome and attributable cost of ventilator-associated pneumonia among intensive care unit patients in a suburban medical center. Critical Care Medicine 2003;31:1312-7.
95. Wunderink R. Radiologic diagnosis of ventilator-associated pneumonia. Chest 117;117(Suppl):188-90.
96. Zhuo H, Yang K, Lynch SV, Dotson RH, Glidden DV, Singh G, et al. Increased mortality of ventilated patients with endotracheal Pseudomonas aeruginosa without clinical signs of infection. Critical Care Medicine 2008;36(9):2495-503.
97. Pugh R, Grant C, Cooke RPD, Dempsey G. Short-course versus prolonged-course antibiotic therapy for hospital-acquired pneumonia in critically ill adults. Cochrane Database of Systematic Reviews 2009, Issue 1. [DOI: 10.1002/14651858.CD007577]
98. Pugh R, Grant C, Cooke RPD, Dempsey G. Short-course versus prolonged-course antibiotic therapy for hospital-acquired pneumonia in critically ill adults. Cochrane Database of Systematic Reviews 2011, Issue 10. [DOI: 10.1002/14651858.CD007577.pub2]